Pall launches pyrofree sterile, ready-to-use glass vials
The packaging has been specifically designed for the processing of small batches such as clinical and technical lots, orphan drugs or personalized medicines.
Pall Life Sciences’ is formally launching its Pyrofree glass vial line for sterile, flexible filling from 2 mL to 20 mL at PDA.
The Pyrofree vials product range is a unique solution providing filling processes with ready-to-use glass vials depyrogenated and sterilized according to industrial operations methods applied in vaccines, biotechnology, and pharmaceutical industries, and in hospitals. The packaging has been specifically designed for the processing of small batches such as clinical and technical lots, orphan drugs or personalized medicines. The Pyrofree vials product range offers a unique opportunity to simplify, facilitate and accelerate the filling of these products.
A pyrogen is defined as any substance that can cause a fever, such as endotoxins. The injection of endotoxins into the blood can cause severe hazard to a patient and in worst case, lead to septic shock. Depyrogenation, or the removal of pyrogens, is therefore a crucial need in the aseptic filling process of parenteral drugs. Primary packaging of injectable drugs is particularly controlled for the absence of pyrogens and any chemical agent which may alter drug substances properties and stability. In this case, sterilization of primary packaging (e.g., by ethylene oxide sterilization) represents a risk of introducing chemical agents into drug substances.
The Pyrofree vials product range addresses these needs thanks to its unique packaging technology, allowing sterilization and depyrogenation of the vials by dry heat in their primary packaging under vacuum. The Pyrofree process results in ready-to-use vials which can be used for the filling of injectable drugs without using washing and depyrogenation equipment from the filling line.
The Pyrofree vials product range consists of Type I clear glass vials of 2 mL, 5 mL, 10 mL and 20 mL, supplied with grey stoppers of 13 mm and 20 mm diameters, made of bromobutyl with Flurotec coating.
Related News
-
News Novartis signs US$3.2 bn subcutaneous delivery deal with Alteogen
Swiss pharma giant secures access to Korean biotech's ALT-B4 hyaluronidase platform in milestone-heavy agreement, marking Alteogen's fourth major licensing deal of 2026 as competition intensifies in the subcutaneous drug delivery space.
-
News Women in Pharma: The philosophy of pharmaceutical leadership
In this latest instalment of our Women in Pharma series, we sit down with Clarissa Sowemimo-Coker, Chief Strategy Officer at Ambrose Healthcare and CPHI Middle East Advisory Board Member.
-
News The PSCI Supplier Partnership - Collaboration for Responsible Supply Chains
About the Pharmaceutical Supply Chain Initiative The Pharmaceutical Supply Chain Initiative (PSCI) is the leading, member-led association for pharmaceutical companies working collaboratively to build responsible supply chains. Founded in 2006 and es... -
News AstraZeneca shares plunge 8.9% after reports of BMS talks
Britain's largest drugmaker lost more than GBP£17 billion in market value following reports of preliminary merger discussions with Bristol Myers Squibb that could create a pharmaceutical giant worth nearly US$400 billion, though investors rem... -
News GSK announces £400 million investment in new Cambridge R&D centre
Pharmaceutical giant to establish flagship research facility on Cambridge Biomedical Campus as part of strategic pipeline acceleration
-
News The CPHI Sustainability Summit - Where Conversation Becomes Collaboration
The Report Was Never the Destination - “The future of pharmaceutical sustainability won’t be shaped by individual organisations working in isolation. It will be shaped by partnerships, shared expertise and the willingness to work diffe... -
News Trump's generic drug tariffs set to reshape global pharmaceutical supply chains
The US president has announced plans to impose tariffs of up to 200% on imported generic medicines from August 2028, giving manufacturers a two-year window to establish domestic production facilities. The move threatens to upend a global supply chain t... -
News Building Safer, More Responsible Pharmaceutical Supply Chains: PSCI Global Audit Insights
The Pharmaceutical Supply Chain Initiative (PSCI) has released its seventh annual Audit Findings Analysis Report, offering unprecedented insights into supplier practices across the global pharmaceutical and healthcare industry.With a record-breaking 24...